A randomised, double-blind, placebo-controlled phase I clinical trial to evaluate the safety, tolerability and immunogenicity of three doses of an adjuvanted group B Streptococcus vaccine in older adults aged 55 to 75.
Group B Streptococcus (GBS) disease is an increasing medical burden in adults. The present phase 1 trial evaluated an adjuvanted GBS vaccine (GBS-AlpN) containing N-terminal domains of four alpha-like proteins (AlpNs) (Alp1N, Alp2/3 N, RibN and AlpCN) in 60 healthy adults and 30 with obesity and/or type 2 diabetes (O/D...